A rumor regarding Ascendis Pharma (ASND) was highlighted in Ben Harrington’s M&A-focused Betaville blog, contacts tell The Fly. Shares of Ascendis are up $4.65, or 2%, to $221.31 in morning trading.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma price target raised to $250 from $245 at RBC Capital
- Ascendis Pharma price target raised to $330 from $322 at Wells Fargo
- Ascendis Pharma: Sustained Commercial Momentum and TransCon Pipeline Catalysts Underpin Buy Rating
- Ascendis Pharma Grants New Employee Warrants, Updates Articles of Association
- Ascendis Pharma: Vision 2030 Growth Story Driven by Yorvipath and Late‑Stage TransCon Pipeline Justifies Buy Rating